Tiphaine Lambert
Overview
Explore the profile of Tiphaine Lambert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
13
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Houdou L, Meynard C, Guillerm S, Mimoun C, Lambert T, Marchand E, et al.
Adv Radiat Oncol
. 2024 Jun;
9(7):101512.
PMID: 38883995
Purpose: This study aims to assess the feasibility and efficacy of high-dose rate (HDR) brachytherapy (BT) administered in a single insertion with 4 treatment sessions for locally advanced cervical cancer...
2.
Helal C, Lambert T, Joly B, Dumont C, Gauthier H, Culine S
Case Rep Oncol
. 2022 Sep;
15(2):745-749.
PMID: 36157695
Heart metastases from urothelial carcinoma of the bladder have rarely been reported in the literature. We present a case complicated by symptomatic disseminated intravascular coagulation in a 67-year-old woman. A...
3.
Lambert T, Pobel C, Colmet-Daage L, Bigorgne A, RaubyY B, Aladro N, et al.
Cancer Treat Res Commun
. 2022 Jul;
32:100611.
PMID: 35905672
PD-L1 and tumor-infiltrating lymphocytes play a key role in the immune escape of cancer, although their prognostic value remains unknown in patients with refractory solid cancer compared to other known...
4.
Jacquier A, Lambert T, Delattre J, Djouadou M, Verine J, Dumont C, et al.
Cancer Lett
. 2021 Jun;
519:105-116.
PMID: 34186161
ILT2 has recently been positioned as a major immune checkpoint in urologic cancers. In clear cell renal cell carcinoma (ccRCC), tumor-infiltrating CD8 T cells expressing ILT2 are a highly cytotoxic...
5.
Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, et al.
Cancer Med
. 2021 Jun;
10(12):3952-3963.
PMID: 34080776
Background: Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown...